<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069168</url>
  </required_header>
  <id_info>
    <org_study_id>TAVR</org_study_id>
    <nct_id>NCT05069168</nct_id>
  </id_info>
  <brief_title>Predictors Of Left Ventricular Systolic Function Recovery After Transcatheter Aortic Valve Replacement</brief_title>
  <official_title>Predictors Of Left Ventricular Systolic Function Recovery After Transcatheter Aortic Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the preprocedural predictors of left ventricular systolic function Recovery after&#xD;
      TAVR&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcific aortic stenosis (AS) is the most common valve disease in the western world requiring&#xD;
      intervention,Although Surgical Aortic Valve Replacement (SAVR) was considered as the first&#xD;
      therapeutic method, approximately one-third of AS patients cannot undergo SAVR due to its'&#xD;
      high risk or contraindication.&#xD;
&#xD;
      Since Transcatheter Aortic Valve Replacement (TAVR)was performed for the first time in&#xD;
      2002,TAVR has emerged as a growing prevalent treatment on severe symptomatic AS with the&#xD;
      procedure initially performed on the inoperable patients with intermediate and high risks.&#xD;
&#xD;
      Recently, the Food and Drug Administration had approved it on low-risk symptomatic subjects.&#xD;
&#xD;
      AS has to be considered a disease of the left ventricle (LV) rather than purely affecting the&#xD;
      aortic valve, Approximately one-third of patients with severe symptomatic AS have LV systolic&#xD;
      dysfunction .&#xD;
&#xD;
      Recovery of LV ejection fraction (LVEF) is associated with improvements in clinical outcomes&#xD;
      after TAVR as shown by a lot of studies.&#xD;
&#xD;
      The Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated that recovery of LV&#xD;
      function in patients with severe symptomatic AS and LV systolic dysfunction who underwent&#xD;
      TAVR, occurs in 40% to 50% of patients .&#xD;
&#xD;
      Higher trans-aortic mean pressure gradient , less LV hypertrophy, Less LV fibrosis and&#xD;
      absence of AF are predictors of recovery of LV function after TAVR .&#xD;
&#xD;
      However, there is still a scanty data about the predictors of LV function recovery after&#xD;
      TAVR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular systolic function recovery by ejection fraction</measure>
    <time_frame>30 days post TAVR</time_frame>
    <description>absolute increase of ≥10% in EF compared with baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular systolic function recovery by STE</measure>
    <time_frame>30 days post TAVR</time_frame>
    <description>Myocardial recovery by STE is defined as a ≥20% relative increase in the magnitude of global longitudinal strain compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>30days post TAVR</time_frame>
    <description>NIHA class .</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Left Ventricular Systolic Function</condition>
  <arm_group>
    <arm_group_label>LVEFrecovery</arm_group_label>
    <description>patient who shows improvement of left ventricular systolic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non LVEF recovery</arm_group_label>
    <description>patient who don't show improvement of left ventricular systolic function</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography before and after TAVR</intervention_name>
    <description>Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.&#xD;
cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.&#xD;
Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)</description>
    <arm_group_label>LVEFrecovery</arm_group_label>
    <arm_group_label>Non LVEF recovery</arm_group_label>
    <other_name>cardiac computed tomography and coronary angiography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with symptomatic severe aortic stenosis eligible for TAVR with LV systolic&#xD;
        function less than 50%&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with symptomatic severe aortic stenosis eligible for TAVR with LV systolic&#xD;
             function less than 50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe Rheumatic or degenerative mitral regurgitation.&#xD;
&#xD;
          -  Previous Valve Replacement.&#xD;
&#xD;
          -  Previous myocardial infarction.&#xD;
&#xD;
          -  Previous Coronary Artery By Bass Graft (CABG)Surgery.&#xD;
&#xD;
          -  Post TAVR significant paravalvular leakage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatem A Helmy</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen sami Anwar</last_name>
    <phone>01013934903</phone>
    <phone_ext>002</phone_ext>
    <email>helensami@aun.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed k fargal Abdelmegid</last_name>
    <phone>01124141899</phone>
    <email>aboel-kassem1970@aun.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Helen Sami Anwar</last_name>
      <phone>01013934903</phone>
      <email>helensami@aun.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Passeri JJ, Elmariah S, Xu K, Inglessis I, Baker JN, Alu M, Kodali S, Leon MB, Svensson LG, Pibarot P, Fearon WF, Kirtane AJ, Vlahakes GJ, Palacios IF, Douglas PS; PARTNER Investigators. Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low EF. Heart. 2015 Mar;101(6):463-71. doi: 10.1136/heartjnl-2014-306737. Epub 2015 Jan 13.</citation>
    <PMID>25586156</PMID>
  </reference>
  <reference>
    <citation>Sato K, Kumar A, Jones BM, Mick SL, Krishnaswamy A, Grimm RA, Desai MY, Griffin BP, Rodriguez LL, Kapadia SR, Obuchowski NA, Popović ZB. Reversibility of Cardiac Function Predicts Outcome After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis. J Am Heart Assoc. 2017 Jul 11;6(7). pii: e005798. doi: 10.1161/JAHA.117.005798.</citation>
    <PMID>28698259</PMID>
  </reference>
  <reference>
    <citation>Han D, Tamarappoo B, Klein E, Tyler J, Chakravarty T, Otaki Y, Miller R, Eisenberg E, Park R, Singh S, Shiota T, Siegel R, Stegic J, Salseth T, Cheng W, Dey D, Thomson L, Berman D, Makkar R, Friedman J. Computed tomography angiography-derived extracellular volume fraction predicts early recovery of left ventricular systolic function after transcatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging. 2021 Jan 22;22(2):179-185. doi: 10.1093/ehjci/jeaa310.</citation>
    <PMID>33324979</PMID>
  </reference>
  <reference>
    <citation>Jeong YJ, Ahn JM, Kang DY, Park H, Ko E, Kim HJ, Kim JB, Choo SJ, Lee SA, Park SJ, Kim DH, Park DW. Incidence, Predictors, and Prognostic Impact of Immediate Improvement in Left Ventricular Systolic Function After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2021 Aug 1;152:99-105. doi: 10.1016/j.amjcard.2021.04.037. Epub 2021 Jun 11.</citation>
    <PMID>34127247</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 25, 2021</last_update_submitted>
  <last_update_submitted_qc>September 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Anwar S Helen</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

